Impact of bupivacaine lozenges on oral mucositis ache: a randomized managed multicenter section II research.
Ache Rep. 2017 Sep;2(5):e619
Authors: Mogensen S, Treldal C, Kristensen CA, Bentzen J, Lawson-Smith L, Petersen J, Andersen O
Introduction: A nonblinded parallel-group randomized managed research investigated the efficacy and tolerability of repeated administration of a bupivacaine lozenge (25 mg) as ache administration for oral mucositis ache in head and neck most cancers sufferers as add-on to straightforward systemic ache administration.
Goal: The first finish level was the distinction between the intervention group (Lozenge group) and the Management group in each day imply ache scores within the oral cavity or pharynx (whichever was increased).
Technique: Fifty sufferers from 2 hospitals in Denmark have been randomized 1:1 to 7 days of remedy with bupivacaine lozenges (taken as much as each 2 hours) plus normal ache remedy minus topical lidocaine (Lozenge group) or normal ache remedy together with topical lidocaine (Management group). The efficacy evaluation included 38 sufferers, as 12 sufferers have been excluded due to modifications in research design and lacking knowledge.
Outcomes: Imply ache within the oral cavity or pharynx (whichever was increased) was considerably decrease 60 minutes after taking lozenges (35 mm [n = 22]) than for the Management group (51 mm [n = 16]) (distinction between teams -16 mm, 95% confidence interval: -26 to -6, P = zero.0032). Ache within the oral cavity was additionally considerably decrease within the Lozenge group (18 mm) vs the Management group (36 mm, P = zero.0002). Pharyngeal mucositis ache didn’t differ considerably (37 mm [Lozenge group] vs 48 mm [Control group], P = zero.0630). No critical adversarial occasions have been reported.
Conclusion: These outcomes present that the bupivacaine lozenge as an add-on to straightforward ache remedy had a clinically important pain-relieving impact in sufferers with oral mucositis.
PMID: 29392234 [PubMed]